Aromasin, with the generic name exemestane, is a medication primarily used in the treatment of breast cancer. It belongs to a class of drugs known as aromatase inhibitors, which function by lowering estrogen levels in the body. Estrogen can promote the growth of hormone receptor-positive breast cancers, so reducing its levels can help slow or stop the progression of the disease.
Exemestane is typically prescribed for postmenopausal women with estrogen receptor-positive early or advanced breast cancer. In early breast cancer, it is often given after initial treatment with tamoxifen, another hormone therapy drug. For advanced cases, Aromasin is used when other treatments have not been effective.
The mechanism of action involves irreversible inhibition of the aromatase enzyme, which is responsible for converting androgens into estrogens in the body. By blocking this conversion, Aromasin significantly reduces the amount of estrogen available to stimulate the growth of breast cancer cells.
Aromasin is taken orally, usually once daily after a meal. Common side effects include hot flashes, fatigue, joint pain, headache, and insomnia. More severe but less common side effects can include bone thinning or osteoporosis, liver function changes, and cardiovascular issues. Regular monitoring by a healthcare provider is essential to manage these potential risks effectively.
Patients with known hypersensitivity to exemestane or any of its ingredients should avoid using this medication. It is also not recommended for premenopausal women, pregnant women, or those breastfeeding, as it can harm the fetus or the nursing baby.
In summary, Aromasin (exemestane) is an effective aromatase inhibitor used primarily in postmenopausal women to treat certain types of breast cancer by significantly reducing estrogen levels, thereby slowing or halting the growth of estrogen-dependent cancer cells.
https://www.hormonerawsource.com/steroid-finished-us-domestic-shipping/steroid-finished-tablets-3-days-to-arrive/stada-aromasin-exemestane-bodybuilting-cas.html
